ClinicalTrials.gg
Not yet recruitingNCT07937852Updated Nov 16, 2026

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)

A Phase 3 interventional study of Fenebrutinib in Multiple Sclerosis, sponsored by Hoffmann-La Roche. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,800
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Multiple Sclerosis by Hoffmann-La Roche — 6 open to participants now, 17 under way, 7 of them phase 3. Multiple Sclerosis · Hoffmann-La Roche.

Planned enrollment
Largest of 31
1,800 · median 134
Started
2027
the only one that year
Phase 3
11 of 35
2 open now
Primary completion
2029-11
later than 13 of 16 live
Registered
35th of 35
by date

Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one has the largest planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2027, is one of 11 in phase 3, reaches primary completion later than 13 of the 16 other live ones, and was the 35th registered.

Multiple Sclerosis

3,269 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

6 of the 35 studies in Multiple Sclerosis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Multiple Sclerosis by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous eligibility and participation in the open-label extension (OLE) phase of an eligible Roche-sponsored parent study, where the participant is receiving fenebrutinib as an medicinal product (IMP)
  • Minimum of 24 weeks exposure to open-label fenebrutinib in parent study
  • Ability and willingness to comply with all aspects of the protocol including completion of procedures, interviews, questionnaires, assessments for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Concurrent participation in any clinical trial (other than the parent study). Participants who withdrew from fenebrutinib treatment in their respective parent study should also be excluded
  • Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which is required
  • Chronic liver disease unless considered stable for >6 months
  • Acute liver disease
  • Cirrhosis ( Class A, B, or C)
  • Gilbert's syndrome
  • (ALT) or alanine aminotransferase (AST) > 1.5 × (ULN)
  • Total greater than 1.5 × ULN
  • A "yes" on any item of the Suicidal Behavior section of the Columbia-Suicide Severity Rating Scale (C-SSRS) or significant risk of a suicide, in the investigator's judgment

Note: Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,800 participants (estimated)

Study arms

  • Experimental
    Fenebrutinib

    Participants receiving fenebrutinib in OLE of their parent study may be eligible for enrollment in this extension study. Participants will continue fenebrutinib treatment at the dosage and route of administration received at the time of rollover from the parent study.

    Drug: Fenebrutinib

Interventions

  • DrugFenebrutinib

    Fenebrutinib will be administered as per the schedule specified in the protocol.

    Also known as: RO7010939; GDC-0853; G02599853

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Change in Expanded Disability Status Scale (EDSS) Score Over Time

    Time frame: Up to approximately 96 weeks

  2. Change in 9-hole Peg Test (9-HPT) Over Time

    Time frame: Up to approximately 96 weeks

  3. Change in Timed 25-foot Walk Test (T25FWT) Over Time

    Time frame: Up to approximately 96 weeks

  4. Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)

    Time frame: Up to approximately 96 weeks

  5. Time to Onset of 24-week Confirmed Disability Progression (CDP24)

    Time frame: Up to approximately 96 weeks

  6. Time to Onset of Modified cCDP24

    Time frame: Up to approximately 96 weeks

  7. Time to Onset of 24-week Confirmed Disability Improvement (CDI24)

    Time frame: Up to approximately 96 weeks

  8. Number of New or Enlarging T2 Magnetic Resonance Imaging (MRI) Lesions

    Time frame: Up to approximately 96 weeks

  9. Number of T1 Hypointense MRI Lesions

    Time frame: Up to approximately 96 weeks

  10. Change in Total Volume of T2 Lesions

    Time frame: Up to approximately 96 weeks

  11. Change in Total Volume of T1 Hypointense Lesions

    Time frame: Up to approximately 96 weeks

  12. Change in Total Brain Volume

    Time frame: Up to approximately 96 weeks

  13. Annualized Relapse Rate (ARR) (for Relapsing Multiple Sclerosis [RMS] Participants Only)

    Time frame: Up to approximately 96 weeks

  14. Change in Patient-reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) Over Time

    Time frame: Up to approximately 96 weeks

  15. Change in Multiple Sclerosis Impact Scale - 29-item (MSIS-29), Version 2 Physical Scale Over Time

    Time frame: Up to approximately 96 weeks

  16. Change in MSIS-29 Psychological Scale Over Time

    Time frame: Up to approximately 96 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Nov 2029, 34 months later.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 34 months is below that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Jan 18, 2027
Primary completionEst.
Nov 30, 2029
CompletionEst.
Nov 30, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937852
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 18, 2027 (estimated)
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Reference Study ID Number: CN45787 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion